Mayo Clinic researchers use pharmacogenetic test prior to chemotherapy to reduce toxic side effects

May 14, 2005

ROCHESTER, Minn. -- Mayo Clinic researchers report that using a genetic screening blood test prior to the start of chemotherapy can decrease the toxicity of a three-drug chemotherapy regimen, thus helping patients tolerate markedly different amounts of each of the three drugs.

Mayo researchers will present these findings at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. The three drugs involved in their investigation are irinotecan, oxaliplatin and capecitabine, and each is individually approved by the Food and Drug Administration (FDA) for the treatment of cancer.

"By using the genetic test prior to the start of chemotherapy, we demonstrated that you can put these drugs together safely," says Mayo Clinic medical oncologist Matthew Goetz, M.D., the study's lead investigator. Co-investigator and oncology researcher Matthew Ames, Ph.D., adds, "We defined different patient populations based on a specific genetic variant to provide a better understanding of how this three-drug regimen will affect individual patients."

Significance of the Mayo Clinic Research

Of the three drugs, irinotecan can be particularly toxic for some patients. Despite the antitumor benefit of each drug, researchers have had difficulty putting the drugs together because the toxicity can be lethal.

The genetic test detects a change in the DNA of a gene that encodes for a protein involved in the metabolism of irinotecan. The test gives scientists advance knowledge of the individual risk for toxicity from irinotecan. As a result, scientists are able to tailor this chemotherapy regimen to the individual, thus reducing toxicity. This kind of customized dosing approach based on a person's genetic makeup is known as "pharmacogenomics" and is the newest frontier of 21st century medicine.

"In the past, a physician knew that the genetic test could predict a higher risk for irinotecan-related toxicity," says Dr. Goetz, "but no one knew what to do with this information with regard to dosing, both for irinotecan and drugs combined with irinotecan. Our study is the first to demonstrate that when you give these drugs in combination, a patient's individual genetic makeup affects the tolerable dose."

The Next Step

Having met the goal of using the genetic test to dose patients, Mayo Clinic researchers will test this combination therapy against specific cancers.
-end-
Collaboration and Support

In addition to Drs. Goetz and Ames, the Mayo Clinic research team included Stephanie Safgren; Joel Reid, Ph.D.; Sumithra Mandrekar, Ph.D.; Alfred Furth; Alex Adjei, M.D., Ph.D.; Axel Grothey, M.D.; Charles Erlichman, M.D.; Joseph Rubin, M.D.; and Mary Kuffel. Richard Goldberg, M.D., of the University of North Carolina, Chapel Hill, N.C., also collaborated on this study.

DISCLOSURE: This study was supported by grants from the National Cancer Institute (NCI).

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

Mayo Clinic

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.